Phase I, open-label study of pasireotide in patients with <i>BRAF-</i>wild type and <i>NRAS</i>-wild type, unresectable and/or metastatic melanoma.

ESMO Open · 2018 · PMC6069912 · PMID 30094073

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

18 Long-acting pasireotide showed a trend towards higher tumour control rate at month 6 (although not statistically significant) and was associated with a longer progression-free survival than long-acting octreotide in patients with metastatic neuroendocrine tumours (NETs). 19 In a recent phase 2 study in patients with lung NETs, pasireoti

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.